Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

  1. Quach, H.
  2. Nooka, A.
  3. Samoylova, O.
  4. Venner, C.P.
  5. Kim, K.
  6. Facon, T.
  7. Spencer, A.
  8. Usmani, S.Z.
  9. Grosicki, S.
  10. Suzuki, K.
  11. Delimpasi, S.
  12. Weisel, K.
  13. Obreja, M.
  14. Zahlten-Kumeli, A.
  15. Mateos, M.-V.
Revue:
British Journal of Haematology

ISSN: 1365-2141,  0007-1048

Année de publication: 2021

Volumen: 194

Número: 4

Pages: 784-788

Type: Lettre

DOI: 10.1111/BJH.17541 GOOGLE SCHOLAR lock_openAccès ouvert editor